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ABSTRACT
We are investigating a strategy for somatic gene therapy to treat human immunodeficiency virus type 1 (HIV-1) infection by intracellular expression of an RNA decoy and a ribozyme. The RNA decoy, consisting of polymeric Tat activation response elements (TARs), is designed to compete for Tat binding in an equilibrium with viral TAR RNA, thereby inhibiting viral replication. The expression of polymeric TAR is regulated by the HIV long terminal repeat (LTR) and transcriptional activation is dependent on the presence of HIV Tat. Our initial studies indicated that plasmids expressing up to 50 tandem copies of TAR RNA (5OTAR) inhibited tatmediated gene expression by >90% in a transient transfection assay. A HIV LTR-driven 50TAR construct was subcloned into a replication-defective retroviral vector to ensure highefficiency gene transfer into T lymphocytes. In addition, a gag RNA-specific ribozyme gene was introduced into the 50TAR containing retroviral vector to enhance the inhibitory effect of the construct (designated TAR-Rib). A human T-cell line (Molt3) was infected (transduced) with the TAR-Rib recombinant retrovirus and challenged with either HIV-1 or simian immunodeficiency virus (SIV). HIV-1 replication was inhibited by 99% in the TAR-Rib-transduced T cells and was maintained over a 14-month period, suggesting that this antiviral strategy represses the formation of escape mutants. Interestingly, the TAR-Rib also inhibited SIV replication in transduced T cells, which suggests that polymeric TAR is a general inhibitor of primate lentiviruses; therefore, the macaque model could be used for further in vivo testing of this antiviral gene therapy strategy.
The Tat protein is a potent transactivator of human immunodeficiency virus type 1 (HIV-1) gene expression (1) and may have additional functions in the pathogenesis of the acquired immunodeficiency syndrome (AIDS), including acting as a vascular cell growth factor, which may be relevant to HIV-associated Kaposi sarcoma (2) (3) (4) (5) . Therefore, Tat is a desirable target for an intervention therapy against HIV-1 infection. Tat activation of HIV-1 gene expression is dependent on a cis-acting element, the Tat activation response element (TAR), which extends from -17 to +80 in the HIV-1 long terminal repeat (LTR) (6) . TAR RNA forms a stable stem-loop structure, and Tat binds to its "bulge" region with high efficiency (7) . This RNA-protein interaction is essential for Tat activation of the HIV-1 LTR (8) . Recently, we have demonstrated that a short polymeric TAR RNA (5 tandem copies) can inhibit Tat-mediated transactivation of the HIV-1 LTR in a transient transfection assay (9) . Having validated the approach of using polymeric TAR RNA decoys, we are
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attempting to develop this strategy further as a somatic gene therapy for the treatment of HIV-1 infection.
MATERIALS AND METHODS
Plasmid Construction. A blunt-ended fragment (Pvu II/Sca I), containing five tandem TARs, was isolated from plasmid LTR-5TAR (9) and ligated (100:1 ratio of vector to insert) into pSPT18 (Pharmacia). Clones containing multiple copies of the STAR insert (up to 45TAR) were isolated and the copy number and orientation were determined by restriction analysis. The polymeric TAR inserts (15TAR and 45TAR) were isolated from the pSPT18 constructs (Sal I/BamHI digestion) and subcloned into Sal I/BamHI-digested LTR-5TAR-chloramphenicol acetyltransferase (CAT) vector, replacing the CAT sequence to generate LTR-20TAR and LTR-5OTAR plasmids (see Fig. 1A Construction of the TAR-Rib Retrovirus Vector and Analysis by PCR. A PCR fragment containing a 65-bp gag-specific ribozyme was subcloned into the BamHI site of pRRE (13) . Eight clones containing the ribozyme sequence were selected after restriction mapping. The orientation of the ribozyme in the pRRE-ribozyme construct was confimed by an in vitro cleavage reaction (13) (see Fig. 2A ).
The Xba I fragment (4.6 kb) containing LTR-5OTAR was inserted into the SnaBI site of the DC vector to generate the Abbreviations: HIV-1, human immunodeficiency virus type 1; LTR, long terminal repeat; TAR, Tat activation response element; SIV, simian immunodeficiency virus; RT, reverse transcriptase; FACS, fluorescence-activated cell sorting; CAT, chloramphenicol acetyltransferase; DC, double copy. tTo whom reprint requests should be addressed.
Proc. Natl. Acad. Sci. USA 90 (1993) 8001 DC-LTR-5OTAR construct. The number of TARs was determined by restriction enzyme analysis. The RRE-ribozyme fragment (see Fig. 2A ) was isolated from pRRE-ribozyme plasmid after HindIII and EcoRI digestion and cloned into the Sca II site of the DC-LTR-5OTAR plasmid. The resulting DC-LTR-5OTAR-RRE-ribozyme was designated TAR-Rib (see Fig. 2B ). The TAR-Rib plasmid was then transfected into the GPe86 ecotropic packaging cell line (14) . After 72 hr, the cell-free supematant was used to infect the GP+envAml2 amphotropic packaging cell line (15) . Three days later, cells were split and selected by using Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS) and G418 sulfate (active weight, 0.5 mg/ml). G418-resistant colonies were pooled to produce replication-defective virus.
Genomic DNA was isolated from TAR-Rib-transduced or control Molt3 cells, and PCR was performed with neo genespecific primers (16) 
RESULTS AND DISCUSSION
Characterization of the Polymeric TAR Plasmids by a Transient Transfection Assay. Plasmids were constructed containing up to 50 copies of the TAR DNA under control of a HIV-1 LTR, which lacks the 5' negative regulatory element (Fig.  1A) . Deletion of the negative regulatory element does not influence the activation of the HIV-1 LTR by Tat, but it does allow higher levels oftranscription compared to the wild-type LTR (18) . Plasmids expressing polymeric TARs were cotransfected into COS cells with LTR-CAT and LTR-Tat. Fig.  1B demonstrates that plasmids containing either 20TAR or 50TAR inhibited tat transactivation of the HIV-1 LTR by >94% in this transient cotransfection assay. Under identical assay conditions, the maximal inhibition achieved using the original LTR-5TAR plasmid was only 75% (Fig. 1B) . These results indicate that increasing the number of TARs results in a corresponding decrease in the level of Tat transactivation of HIV-1 LTR, suggesting an increased inhibitory effect on viral replication.
Intracellular localization of the polymeric TAR RNA in the transfected cells was determined by in situ hybridization. A radiolabeled polymeric TAR DNA probe was used under nondenaturing conditions for hybridization. These conditions restrict the hybridization of the probe to cellular RNA and minimize the binding to DNA. This analysis demonstrated that the polymeric TAR RNA was predominantly concentrated in the nucleus (Fig. 1C) . The in situ localization ofpolymeric TAR RNA is consistent with our hypothesis that the decoy can compete with the HIV LTR for Tat binding in the nucleus (19) , resulting in a substantial reduction in transactivation. Generation of TAR-Rib Retroviral Vector and Transduced T Cells. To ensure high-efficiency gene transfer to the target cells, a replication-defective retroviral vector, based on Moloney murine leukemia virus, was used (kindly provided by E. Gilboa, Sloan-Kettering Institute for Cancer Research, New York). To achieve tat-inducible expression, the LTR-5OTAR fragment was subcloned into the U5 region of the 3' LTR of the DC retrovirus vector (20) . Reverse transcription and provirus formation with this vector results in duplication of the inserted gene and, in this case, establishment of two copies of the LTR-50TAR gene for every integration event into the genome of the transduced cell. To further enhance the inhibitory effect of the retroviral construct, we introduced a gag RNA-specific ribozyme gene (13) sequence. The fragment containing the gag-specific ribozyme (RRE-ribozyme) included a rev-responsive element to facilitate transport of the ribozyme RNA to the cytoplasm. Fig. 2A demonstrates the catalytic activity of the RREribozyme gene in an in vitro RNA cleavage reaction. By introducing the RRE-ribozyme gene, we were attempting to generate a bifunctional construct that could (i) function in the nucleus as a Tat-binding TAR decoy, or (ii) function in the cytoplasm as a HIV RNA-specific ribozyme. We used this DC-LTR-5OTAR-RRE-ribozyme construct, designated TAR-Rib (Fig. 2B) , and the unmodified control DC vector to produce amphotropic retrovirus. This recombinant virus was used to infect (transduce) a T-cell line (Molt3). Transduced cells were then selected with a neomycin analog (G418 sulfate) without single cell cloning. The presence ofretroviral genomes was confirmed by PCR analysis (Fig. 2C) .
Inhibition of HIV-1 Replication in the TAR-Rib-Transduced T Cells. After G418 selection, T-cell lines transduced with the TAR-Rib construct or the DC vector were challenged with HIV-1iiIB. During the first 20 days, HIV replication was significantly inhibited in the TAR-Rib-transduced T cells compared with the vector control (Fig. 3A) . In both cell lines, however, viral replication ultimately resulted in observable cytopathic effects, characterized by a significant portion of cells forming syncytia. After 3 months of continuous culture, there was no further evidence of syncytia formation, although virus replication was still detectable by RT assay or p24 ELISA. We tested the p24 levels in the culture supernatants and cellular lysates of the TAR-Rib or DC vector-transduced Molt3 cells and compared them to the untransduced HIV-1-infected Molt3 control cells (Fig. 3B) . Surprisingly, there was an unexpected reduction in the amount of p24 in the culture supernatants of the DC vector-transduced cells compared to the untransduced Molt3 cells. However, the amount of p24 detected in the cellular lysates was not significantly different. These results suggested that either the vector or the G418 selection has some effects on virion release. Proc. Natl. Acad. Sci. USA 90 (1993) of CD4 receptors. After 14 months of continuous culture, inhibition of HIV-1 replication in the TAR-Rib-transduced T cells exceeded 99%. The residual low-level virus replication in the TAR-Rib-transduced T cells supported our hypothesis that the TAR RNA decoy competes for tat binding in an equilibrium with the proviral TAR RNA. In addition, we examined the cultures by transmission electron microscopy (Fig. 3C) . Quantitative analysis of the number of viral particles showed abundant HIV-1 particles (typically 80-90 virus particles per cell) in the DC vector control cells and few mature particles (<10 virus particles per cell) in the TARRib-transduced T cells.
Since we had already established that the gag RNAspecific RRE-ribozyme gene was active in vitro ( Fig. 2A) , a primer-extension experiment was designed to detect RNA cleavage products in the HIV-1-infected TAR-Rib-transduced T cells. However, the significant inhibition of HIV-1 replication by the TAR RNA decoy resulted in a highly reduced yield of viral RNA. Since the amount of the RNA cleavage product was difficult to detect at the given sensitivity of current assays, we do not known whether the addition of an anti-gag ribozyme gene augments the inhibitory activity of the LTR-5OTAR construct.
Inhibition of SIV Replication in the TAR-Rib-Transduced T Cells. We were interested in determining whether the TARRib retroviral construct could inhibit the replication of distantly related retroviruses. Therefore, we infected the TARRib and vector-transduced Molt3 cells with SIVmac251. Up to 90% inhibition of SIV replication was observed in the TARRib-transduced T cells when compared to the DC vectortransduced cells (Fig. 4) , although the SIV infection did not result in syncytia formation. SIV-infected cells were also examined by electron microscopy. Quantitative analysis infection, resulting in a reduced but persistent virion release responsible for syncytia formation and cell death in HIV-1-infected Molt3 cells. This low-level expression may be due to either spontaneous mutations in the TAR-Rib construct during packaging as retroviral particles or possibly transcriptional interference from a cellular promoter occurring after integration (23) . Another explanation could involve the Tatdependent regulation of the TAR-Rib construct. Tat must be produced by the HIV-1 provirus to activate transcription of TAR-Rib from a HIV-1 LTR, and this will result in the release of some infectious HIV-1 particles. This persistent replication of HIV-1 in the TAR-Rib-transduced cells can induce syncytia formation with uninfected cells, resulting in a selective advantage for T cells expressing low levels of surface CD4 antigen. This may explain the results of the FACS analysis in which we observed a reduction in surface CD4 expression in TAR-Rib-transduced and HIV-1-infected Molt3 cells over time. Since there is no evidence for significant syncytia formation in vivo, we would not expect this selection to be a problem in our gene therapy strategy.
Somatic gene therapy is an exciting recent development in biomedical research (24, 25) . We have shown that regulated expression of an RNA decoy can inhibit HIV-1 and SIV replication in T cells. The HIV-1 LTR-driven polymeric TARs can only be transcribed in the presence of Tat protein after virus infection. If the cell is not infected, the inhibitory gene will not be expressed. Regulation of gene expression in a gene therapy strategy is extremely important because we do not know that long-term constitutive expression of TAR or any other foreign gene will not be toxic to the cells. Combining the TAR decoys with anti-gag ribozyme gives an additional advantage to the inhibitory gene: one RNA transcript has dual function in blocking the activity of Tat protein and the translation of the gag mRNA. This inhibitory RNA blocked HIV-1 replication in T cells by >99% over a 14-month period in vitro in the absence of escape mutants, indicating that this strategy may have beneficial long-term effects in vivo. In addition, the demonstration of SIV inhibition opens the way for use ofthe SIV infection of macaques as a model for HIV-1 infection in humans.
